BrightSpring Q2 2026 earnings: Pharmacy economics lift profit and guidance

BrightSpring Health Services (NASDAQ: BTSG) reported Q2 2026 revenue of $3.873 billion, up 23.0% from $3.148 billion, while diluted EPS from continuing operations rose to $0.39 from $0.04. Adjusted EBITDA increased 44.2% to $205.5 million, although quarterly operating cash flow declined to $43.9 million. The results cover the quarter ended June 30, 2026, and reflect continuing operations following the March 30 divestiture of Community Living.

Core financial results

Revenue increased by approximately $725 million, while gross profit grew faster than sales as pharmacy gross profit per prescription improved. Selling, general and administrative expenses rose 11.1% to $362.4 million, well below the 31.5% increase in gross profit, allowing operating income and margins to expand.

The comparison also benefited from lower acquisition, integration, restructuring and divestiture-related expenses. Total adjustments used to calculate adjusted EBITDA fell to $33.7 million from $52.1 million.

Including discontinued operations, consolidated net income was $84.2 million and diluted EPS was $0.38. Adjusted EBITDA and adjusted EPS are non-GAAP measures.

Business and segment performance

Both segments recorded double-digit revenue and EBITDA growth. Pharmacy Solutions remained the larger business, accounting for approximately 88% of total revenue, while Provider Services posted the faster revenue increase.

Pharmacy prescription volume was essentially unchanged at 10.84 million. The segment’s growth instead coincided with revenue per prescription rising 22% to $314.20 and gross profit per prescription increasing 28% to $27.50. The disclosed data do not separate the effects of drug prices, service mix or other factors on these per-prescription metrics.

In Provider Services, home health average daily census increased 54% to 46,448, compared with 9% growth in people served by Rehab Care and 1% growth in Personal Care. Home health was therefore the standout operating metric, although the company did not provide an organic-versus-acquired growth breakdown.

Profit growth did not translate into higher quarterly cash flow

Profitability improved across multiple measures. Gross margin expanded by approximately 0.8 percentage points, operating margin by about 1.8 points and adjusted EBITDA margin by roughly 0.8 points. Net interest expense also declined to $36.9 million from $38.8 million.

Quarterly operating cash flow nevertheless fell 10.5% to $43.9 million. A $78.3 million cash use from prepaid expenses and other current assets was a notable drag, while the $107.1 million accounts-payable cash contribution recorded in Q2 2025 did not recur. The longer six-month comparison was better: operating cash flow increased 10.7% to $166.9 million from $150.7 million.

BrightSpring ended June with $550.4 million in cash. During the first half, the company received $810.9 million from the sale of discontinued operations, repaid $320.5 million of debt and spent $120 million on share repurchases. Q2 alone included $308.1 million of debt repayments and $60 million of repurchases, including 1,026,465 shares acquired from the underwriter alongside the secondary offering.

Leverage declined to 2.15 times from 2.27 times at March 31. BrightSpring also modified and refinanced portions of its First Lien Facility after a $300 million paydown, which the company said generated interest savings.

Full-year 2026 guidance

BrightSpring raised its full-year revenue and adjusted EBITDA outlook, but the previous ranges were not included in the release, so the size of the increase cannot be quantified. The guidance excludes Community Living and the effects of future acquisitions.

The acquired Amedisys and LHC branches are expected to contribute approximately $35 million of adjusted EBITDA in 2026. Because adjusted EBITDA guidance is non-GAAP, BrightSpring did not provide a reconciliation to projected GAAP net income.

Recent insider transactions

The supplied transaction records show sales by KKR and three executives on June 5, 2026, during the same month as the secondary offering disclosed by BrightSpring. The reported values below describe the transactions but do not establish the sellers’ views about the company’s prospects.

The same dataset also recorded derivative-security exercises by Rousseau, Phipps and Nalley at $6.37 per share before the reported sales.

Risks investors should monitor

• Dependence on pharmacy unit economics: Pharmacy revenue rose 22% even though prescription volume was flat. Future performance therefore depends in part on maintaining favorable revenue and gross profit per prescription, which can be affected by drug pricing, utilization, supplier terms, PBM contracts and reimbursement.
• Margin execution: Full-year adjusted EBITDA growth guidance of 32.8% to 36.8% is materially above projected revenue growth of 17.0% to 19.5%. Delivering the outlook requires continued operating leverage despite higher corporate costs.
• Acquisition integration: The outlook includes approximately $35 million of adjusted EBITDA from the Amedisys and LHC branches. Integration delays, collection issues or higher costs could reduce that contribution.
• Cash conversion and leverage: Q2 operating cash flow declined despite substantial profit growth, reflecting working-capital pressure. Leverage improved after the debt paydown but remained 2.15 times, and quarterly net interest expense was still $36.9 million.
• Provider reimbursement and staffing: Provider Services growth was led by a sharp increase in home health census. Medicare and Medicaid reimbursement changes or difficulty recruiting and retaining clinical staff could affect the segment’s revenue and margins.

Summary

BrightSpring’s Q2 2026 results showed revenue growth across both segments, with pharmacy per-prescription economics and home health census supporting faster growth in gross profit and adjusted EBITDA. Margin expansion and lower adjustment costs strengthened earnings, while weaker quarterly cash conversion provided a counterpoint. The main issues ahead are execution against the raised guidance, realization of the expected acquisition contribution and whether pharmacy profitability and operating cash flow can remain supportive.